Trials
MRD trials
The curated index is a sourced list of studies. Accruing is the live ClinicalTrials.gov set of studies that are recruiting or not yet recruiting. DYNAMIC-III is not in the curated index because it is registered in Australia and New Zealand, not with an NCT id.
Recruiting and not-yet-recruiting studies that use ctDNA, cfDNA, or MRD in eligibility, a treatment decision, or a primary or secondary endpoint, plus observational studies focused on that testing. 1123 studies from 2267 registry records. Hematologic trials that list MRD only as a secondary endpoint are listed separately. Last synced Nov 18, 2026, 2:04 PM EST.
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
National Cancer Institute (NCI) · 505 locations · Updated 2026-11-12
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
NRG Oncology · 259 locations · Updated 2026-10-23
The Impact of Time-of-day Administration of EV/P on Objective Response Rate in Adults With Advanced Bladder Cancer
Guliz Ozgun · 5 locations · Updated 2026-10-01
Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer
University of Rome Tor Vergata · 1 locations · Updated 2025-07-24
Genomic ctDNA-Informed De-escalation And Neoadjuvant Chemotherapy Omission in Cystectomy
Case Comprehensive Cancer Center · 1 locations · Updated 2026-11-18
Risk-Enabled Therapy After Initiating EV/Pembro for Bladder Cancer
Fox Chase Cancer Center · 1 locations · Updated 2026-11-02
Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?
Tianjin Medical University Second Hospital · 4 locations · Updated 2026-10-15
Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma
Yale University · 2 locations · Updated 2026-10-07
A Phase 2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Patients With Muscle-Invasive Urothelial Cancer
University of Utah · 1 locations · Updated 2026-09-16
Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma
University of Florida · Locations not reported · Updated 2026-09-14
Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC
The Netherlands Cancer Institute · 3 locations · Updated 2026-06-25
Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer
Tianjin Medical University Second Hospital · 3 locations · Updated 2026-05-26
Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence
University of California, Irvine · 1 locations · Updated 2026-04-30
Circulating Tumor DNA Response In Urothelial Cancer
University of Oklahoma · 1 locations · Updated 2026-02-02
A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral Resection
RenJi Hospital · 1 locations · Updated 2025-08-26
Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · 1 locations · Updated 2024-07-30
Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer
Tianjin Medical University Second Hospital · 7 locations · Updated 2026-11-03
Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)
Fox Chase Cancer Center · 2 locations · Updated 2026-11-02
Circulating Tumor DNA (ctDNA) in High Grade Upper Tract Urothelial Cancer (UTUC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · 1 locations · Updated 2026-10-29
Outcomes for IR and High Risk (HR) Non-muscle Invasive Bladder Cancer (NMIBC) and ctDNA-based Biomarkers for Response and Recurrence in Muscle Invasive Bladder Cancer (MIBC)
Bladder Cancer Advocacy Network · 1 locations · Updated 2026-10-26
Urinary Cell-Free DNA Liquid Biopsy for Urothelial Cancer Diagnosis and Origin Identification
Ruijin Hospital · 1 locations · Updated 2026-10-22
Tumor-informed ctDNA in Muscle-invasive Bladder Cancer for Evaluation of Residual/Recurrent Disease - the TiMBER Trial
OHSU Knight Cancer Institute · 1 locations · Updated 2026-08-14
Validation of a Circulating Tumor DNA Blood Test in Muscle-Invasive Bladder and Upper Tract Urothelial Cancer
AZ Sint-Lucas Gent · 1 locations · Updated 2026-08-10
T1G3R-1 Trial: Detectability and Prognostic Value of ctDNA in T1 G3 Bladder Cancer
University Hospital, Basel, Switzerland · 2 locations · Updated 2026-05-18
Feasibility Study of Urinary cfDNA Analysis as a Non-invasive Monitoring Tool in Patients With Prostate or Bladder Cancer
Institut Cancerologie de l'Ouest · Locations not reported · Updated 2026-03-16
Korean Prospective Upper Tract Urothelial Carcinoma Cohort
Samsung Medical Center · 1 locations · Updated 2026-03-05
The Guiding Value of Liquid Biopsy Based on Urinary Tumor DNA/RNA in the Second Transurethral Resection of High-risk Non-muscle Invasive Bladder Cancer
Tianjin Medical University Second Hospital · 2 locations · Updated 2026-03-03
Using Liquid Biopsy Testing to Identify, Monitor, Predict Recurrence in Urothelial Carcinoma
Tianjin Medical University Second Hospital · 1 locations · Updated 2026-03-02
Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma
RenJi Hospital · 1 locations · Updated 2025-12-09
Prospective Validation Study of High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Cancer
Tampere University Hospital · 8 locations · Updated 2025-10-10
Development of Urologic Registry for Personalized Medicine in Patients With Urological Malignancy by Analyzing Circulating Tumor DNA
Yonsei University · 1 locations · Updated 2019-12-13
Status can change after this sync. The curated list is the other view on this page. Evidence holds the published results.